Modulation of ligand-gated ion channels by antidepressants and antipsychotics

Molecular Neurobiology

Volumn 35, Issue 2, 2007, Pages 160-174

  Rammes, Gerhard ^a,b   Rupprecht, Rainer ^c  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Allosteric; Antagonist; Antidepressants; Antipsychotics; Ligand gated ion channels; Modulator; Psychopharmacological drug; Synaptic transmission

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ANTIDEPRESSANT AGENT; ION CHANNEL; NEUROLEPTIC AGENT; NICOTINIC RECEPTOR; SEROTONIN 3 RECEPTOR;

ALLOSTERISM; CHANNEL GATING; DRUG MECHANISM; HUMAN; LIGAND BINDING; PSYCHOPHARMACOLOGY; REVIEW;

EID: 36248949621     PISSN: 08937648     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12035-007-0006-1     Document Type: Review

References (160)

1. Pacher P, Kohegyi E, Kecskemeti V, Furst S (2001) Current trends in the development of new antidepressants. Curr Med Chem 8:89-100
2. Blakely RD (2001) Physiological genomics of antidepressant targets: keeping the periphery in mind. J Neurosci 21:8319-8323
3. Duman RS, Heninger GR, Nestler EJ (1997) A molecular and cellular theory of depression. Arch Gen Psychiatry 54:597-606
4. Holsboer F, Barden N (1996) Antidepressants and hypothalamic-pituitary- adrenocortical regulation. Endocr Rev 17:187-205
5. Webster EL, Lewis DB, Torpy DJ, Zachman EK, Rice KC, Chrousos GP (1996) In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 137:5747-5750
6. Frazer A (2001) Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies. J Clin Psychiatry 62(Suppl 12):16-23
7. Parsons CG, Danysz W, Zieglgansberger W (2005) Excitatory amino acid neurotransmission. Handb Exp Pharmacol 249-303
8. Paul IA, Skolnick P (2003) Glutamate and depression: clinical and preclinical studies. Ann N Y Acad Sci 1003:250-272
9. Palucha A, Pilc A (2005) The involvement of glutamate in the pathophysiology of depression. Drug News Perspect 18:262-268
10. Maj J (1991) Antidepressants given repeatedly: pharmacological evaluation of their action. Pol J Pharmacol Pharm 43:241-254
11. Moryl E, Danysz W, Quack G (1993) Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol Toxicol 72:394-397
12. Papp M, Moryl E (1994) Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur J Pharmacol 263:1-7
13. Przegalinski E, Tatarczynska E, Deren-Wesolek A, Chojnacka-Wojcik E (1997) Antidepressant-like effects of a partial agonist at strychnine- insensitive glycine receptors and a competitive NMDA receptor antagonist. Neuropharmacology 36:31-37
14. Krebs M, Leopold K, Hinzpeter A, Schaefer M (2006) Neuroprotective agents in schizophrenia and affective disorders. Expert Opin Pharmacother 7:837-848
15. Huang NY, Layear RT, Skolnick P (1997) Is an adaptation of NMDA receptors an obligatory step in antidepressant action? In: Skolnick P (ed) Antidepressants: new pharmacologic strategies. Humana Press, Totowa, NJ, pp 125-143
16. Paul IA, Layer RT, Skolnick P, Nowak G (1993) Adaptation of the NMDA receptor in rat cortex following chronic electroconvulsive shock or imipramine. Eur J Pharmacol 247:305-311
17. Paul IA, Nowak G, Layer RT, Popik P, Skolnick P (1994) Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J Pharmacol Exp Ther 269:95-102
18. Kole MH, Swan L, Fuchs E (2002) The antidepressant tianeptine persistently modulates glutamate receptor currents of the hippocampal CA3 commissural associational synapse in chronically stressed rats. Eur J Neurosci 16:807-816
19. Watanabe M, Inoue Y, Sakimura K, Mishina M (1993) Distinct distributions of five N-methyl-D-aspartate receptor channel subunit mRNAs in the forebrain. J Comp Neurol 338:377-390
20. Sernagor E, Kuhn D, Vyklicky L Jr, Mayer ML (1989) Open channel block of NMDA receptor responses evoked by tricyclic antidepressants. Neuron 2:1221-1227
21. Ueta K, Suzuki T, Uchida I, Mashimo T (2004) In vitro inhibition of recombinant ligand-gated ion channels by high concentrations of milnacipran. Psychopharmacology (Berl) 175:241-246
22. Puozzo C, Leonard BE (1996) Pharmacokinetics of milnacipran in comparison with other antidepressants. Int Clin Psychopharmacol 11(Suppl 4):15-27
23. Rudolph U, Mohler H (2004) Analysis of GABAA receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse genetics. Annu Rev Pharmacol Toxicol 44:475-498
24. McKernan RM, Whiting PJ (1996) Which GABAA-receptor subtypes really occur in the brain? Trends Neurosci 19:139-143
25. Nutt DJ, Malizia AL (2001) New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry 179:390-396
26. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ (2002) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry 3:171-199
27. Griffin LD, Mellon SH (1999) Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci U S A 96:13512-13517
28. Uzunov DP, Cooper TB, Costa E, Guidotti A (1996) Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography. Proc Natl Acad Sci U S A 93:12599-12604
29. Rupprecht R, Holsboer F (1999) Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci 22:410-416
30. Romeo E, Strohle A, Spalletta G, di Michele F, Hermann B, Holsboer F, Pasini A, Rupprecht R (1998) Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry 155:910-913
31. Robinson RT, Drafts BC, Fisher JL (2003) Fluoxetine increases GABA(A) receptor activity through a novel modulatory site. J Pharmacol Exp Ther 304:978-984
32. Baker GB, Wong JT, Yeung JM, Coutts RT (1991) Effects of the antidepressant phenelzine on brain levels of gamma-aminobutyric acid (GABA). J Affect Disord 21:207-211
33. Korf J, Venema K (1983) Desmethylimipramine enhances the release of endogenous GABA and other neurotransmitter amino acids from the rat thalamus. J Neurochem 40:946-950
34. Tanay VA, Glencorse TA, Greenshaw AJ, Baker GB, Bateson AN (1996) Chronic administration of antipanic drugs alters rat brainstem GABAA receptor subunit mRNA levels. Neuropharmacology 35:1475-1482
35. Barnes NM, Sharp T (1999) A review of central 5-HT receptors and their function (review, 650 refs). Neuropharmacology 38:1083-1152
36. van Hooft JA, Vijverberg HP (2000) 5-HT(3) receptors and neurotransmitter release in the CNS: a nerve ending story? Trends Neurosci 23:605-610
37. Ronde P, Nichols RA (1998) High calcium permeability of serotonin 5-HT3 receptors on presynaptic nerve terminals from rat striatum. J Neurochem 70:1094-1103
38. Sugita S, Shen KZ, North RA (1992) 5-hydroxytryptamine is a fast excitatory transmitter at 5-HT3 receptors in rat amygdala. Neuron 8:199-203
39. Roerig B, Nelson DA, Katz LC (1997) Fast synaptic signaling by nicotinic acetylcholine and serotonin 5-HT3 receptors in developing visual cortex. J Neurosci 17:8353-8362
40. MacDermott AB, Role LW, Siegelbaum SA (1999) Presynaptic ionotropic receptors and the control of transmitter release. Annu Rev Neurosci 22:443-485
41. Costall B, Naylor R (2000) Neuropharmacology of 5-HT3 receptor ligands. In: Baumgarten HG, Gothert M (eds) Serotoninergic Neurons and 5-HT Receptors in the CNS. Springer, Berlin Heidelberg New York, pp 409-438
42. Eisensamer B, Rammes G, Gimpl G, Shapa M, Ferrari U, Hapfelmeier G, Bondy B, Parsons C, Gilling K, Zieglgänsberger W, Holsboer F, Rupprecht R (2003) Antidepressant are functional antagonists at the serotonin type 3 (5-HT3) receptor. Mol Psychiatry 8:994-1007
43. Tecott LH, Maricq AV, Julius D (1993) Nervous system distribution of the serotonin 5-HT3 receptor mRNA. Proc Natl Acad Sci U S A 90:1430-1434
44. Kilpatrick GJ, Jones BJ, Tyers MB (1987) Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature 330:746-748
45. Nakagawa Y, Ishima T, Takashima T (1998) The 5-HT3 receptor agonist attenuates the action of antidepressants in the forced swim test in rats. Brain Res 786:189-193
46. Rodgers RJ, Cole JC, Tredwell JM (1995) Profile of action of 5-HT3 receptor antagonists, ondansetron and WAY 100289, in the elevated plus-maze test of anxiety of mice. Psychopharmacology (Berl) 117:306-312
47. Fan P (1994) Facilitation of 5-hydroxytryptamine3 receptor desensitization by fluoxetine. Neuroscience 62:515-522
48. Breitinger HG, Geetha N, Hess GP (2001) Inhibition of the serotonin 5-HT3 receptor by nicotine, cocaine, and fluoxetine investigated by rapid chemical kinetic techniques. Biochemistry 40:8419-8429
49. Barnes EM Jr (1996) Use-dependent regulation of GABAA receptors. Int Rev Neurobiol 39:53-76
50. Calkin PA, Barnes EM Jr (1994) gamma-Aminobutyric acid-A (GABAA) agonists down-regulate GABAA/benzodiazepine receptor polypeptides from the surface of chick cortical neurons. J Biol Chem 269:1548-1553
51. Miranda JD, Barnes EM Jr (1997) Repression of gamma-aminobutyric acid type A receptor alpha1 polypeptide biosynthesis requires chronic agonist exposure. J Biol Chem 272:16288-16294
52. Eisensamer B, Uhr M, Meyr S, Gimpl G, Deiml T, Rammes G, Lambert JJ, Zieglgansberger W, Holsboer F, Rupprecht R (2005) Antidepressants and antipsychotic drugs colocalize with 5-HT3 receptors in raft-like domains. J Neurosci 25:10198-10206
53. Guirland C, Suzuki S, Kojima M, Lu B, Zheng JQ (2004) Lipid rafts mediate chemotropic guidance of nerve growth cones. Neuron 42:51-62
54. Hering H, Lin CC, Sheng M (2003) Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. J Neurosci 23:3262-3271
55. Ledesma MD, Simons K, Dotti CG (1998) Neuronal polarity: essential role of protein-lipid complexes in axonal sorting. Proc Natl Acad Sci U S A 95:3966-3971
56. Lang T, Bruns D, Wenzel D, Riedel D, Holroyd P, Thiele C, Jahn R (2001) SNAREs are concentrated in cholesterol-dependent clusters that define docking and fusion sites for exocytosis. EMBO J 20:2202-2213
57. Chamberlain LH, Burgoyne RD, Gould GW (2001) SNARE proteins are highly enriched in lipid rafts in PC12 cells: implications for the spatial control of exocytosis. Proc Natl Acad Sci U S A 98:5619-5624
58. Suzuki T, Ito J, Takagi H, Saitoh F, Nawa H, Shimizu H (2001) Biochemical evidence for localization of AMPA-type glutamate receptor subunits in the dendritic raft. Brain Res Mol Brain Res 89:20-28
59. Eckert GP, Igbavboa U, Muller WE, Wood WG (2003) Lipid rafts of purified mouse brain synaptosomes prepared with or without detergent reveal different lipid and protein domains. Brain Res 962:144-150
60. Wetzel CH, Hermann B, Behl C, Pestel E, Rammes G, Zieglgansberger W, Holsboer F, Rupprecht R (1998) Functional antagonism of gonadal steroids at the 5-Hydroxytryptamine type 3 receptor. Mol Endocrinol 12:1441-1451
61. Galzi JL, Changeux JP (1995) Neuronal nicotinic receptors: molecular organization and regulations. Neuropharmacology 34:563-582
62. Lindstrom J (1996) Neuronal nicotinic acetylcholine receptors. Ion Channels 4:377-450
63. Lukas RJ, Bencherif M (1992) Heterogeneity and regulation of nicotinic acetylcholine receptors. Int Rev Neurobiol 34:25-131
64. Lukas RJ, Changeux JP, Le Novere N, Albuquerque EX, Balfour DJ, Berg DK, Bertrand D, Chiappinelli VA, Clarke PB, Collins AC, Dani JA, Grady SR, Kellar KJ, Lindstrom JM, Marks MJ, Quik M, Taylor PW, Wonnacott S (1999) International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev 51:397-401
65. Millar NS (2003) Assembly and subunit diversity of nicotinic acetylcholine receptors (review, 80 refs). Biochem Soc Trans 31:869-874
66. Caldarone BJ, Harrist A, Cleary MA, Beech RD, King SL, Picciotto MR (2004) High-affinity nicotinic acetylcholine receptors are required for antidepressant effects of amitriptyline on behavior and hippocampal cell proliferation. Biol Psychiatry 56:657-664
67. Shytle RD, Silver AA, Lukas RJ, Newman MB, Sheehan DV, Sanberg PR (2002) Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry 7:525-535
68. Arita M, Wada A, Takara H, Izumi F (1987) Inhibition of 22Na influx by tricyclic and tetracyclic antidepressants and binding of [3H]imipramine in bovine adrenal medullary cells. J Pharmacol Exp Ther 243:342-348
69. Izaguirre V, Fernandez-Fernandez JM, Cena V, Gonzalez-Garcia C (1997) Tricyclic antidepressants block cholinergic nicotinic receptors and ATP secretion in bovine chromaffin cells. FEBS Lett 418:39-42
70. Shaker N, Eldefrawi AT, Miller ER, Eldefrawi ME (1981) Interaction of tricyclic antidepressants with the ionic channel of the acetylcholine receptor of Torpedo electric organ. Mol Pharmacol 20:511-518
71. Park TJ, Shin SY, Suh BC, Suh EK, Lee IS, Kim YS, Kim KT (1998) Differential inhibition of catecholamine secretion by amitriptyline through blockage of nicotinic receptors, sodium channels, and calcium channels in bovine adrenal chromaffin cells. Synapse 29:248-256
72. Schofield GG, Witkop B, Warnick JE, Albuquerque EX (1981) Differentiation of the open and closed states of the ionic channels of nicotinic acetylcholine receptors by tricyclic antidepressants. Proc Natl Acad Sci U S A 78:5240-5244
73. Garcia-Colunga J, Awad JN, Miledi R (1997) Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac). Proc Natl Acad Sci USA 94:2041-2044
74. Hennings EC, Kiss JP, Vizi ES (1997) Nicotinic acetylcholine receptor antagonist effect of fluoxetine in rat hippocampal slices. Brain Res 759:292-294
75. Fryer JD, Lukas RJ (1999) Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function. J Neurochem 72:1117-1124
76. Hennings EC, Kiss JP, De Oliveira K, Toth PT, Vizi ES (1999) Nicotinic acetylcholine receptor antagonistic activity of monoamine uptake blockers in rat hippocampal slices. J Neurochem 73:1043-1050
77. Miller DK,Wong EH, ChesnutMD, Dwoskin LP (2002) Reboxetine: functional inhibition of monoamine transporters and nicotinic acetylcholine receptors. J Pharmacol Exp Ther 302:687-695
78. Lopez-Valdes HE, Garcia-Colunga J (2001) Antagonism of nicotinic acetylcholine receptors by inhibitors of monoamine uptake. Mol Psychiatry 6:511-519
79. Gumilar F, Arias HR, Spitzmaul G, Bouzat C (2003) Molecular mechanisms of inhibition of nicotinic acetylcholine receptors by tricyclic antidepressants. Neuropharmacology 45:964-976
80. Slemmer JE, Martin BR, Damaj MI (2000) Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295:321-327
81. Fryer JD, Lukas RJ (1999) Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 288:88-92
82. Martin BR, Onaivi ES, Martin TJ (1989) What is the nature of mecamylamine's antagonism of the central effects of nicotine? Biochem Pharmacol 38:3391-3397
83. Rose JE, Behm FM, Westman EC, Levin ED, Stein RM, Ripka GV (1994) Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin Pharmacol Ther 56:86-99
84. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallah MA, Schroeder DR, Glover PN, Sullivan CR, Croghan IT, Sullivan PM (1997) A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337:1195-1202
85. Carlsson ML (1995) The selective 5-HT2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse - implications for psychosis. J Neural Transm Gen Sect 100:225-237
86. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M (1998) Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155:761-767
87. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 94:2569-2574
88. Hietala J, Syvalahti E, Vuorio K, Nagren K, Lehikoinen P, Ruotsalainen U, Rakkolainen V, Lehtinen V, Wegelius U (1994) Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch Gen Psychiatry 51:116-123
89. Laruelle M, Iyer RN, al-Tikriti MS, Zea-Ponce Y, Malison R, Zoghbi SS, Baldwin RM, Kung HF, Charney DS, Hoffer PB, Innis RB, Bradberry CW (1997) Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 25:1-14
90. Kinon BJ, Lieberman JA (1996) Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Berl) 124:2-34
91. Newcomer JW, Faustman WO, Zipursky RB, Csernansky JG (1992) Zacopride in schizophrenia: a single-blind serotonin type 3 antagonist trial. Arch Gen Psychiatry 49:751-752
92. Goff DC, Coyle JT (2001) The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158:1367-1377
93. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmuller B (1980) Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 20:379-382
94. Parsons CG, Danysz W, Quack G (1998) Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect 11:523-569
95. Breese GR, Knapp DJ, Moy SS (2002) Integrative role for serotonergic and glutamatergic receptor mechanisms in the action of NMDA antagonists: potential relationships to antipsychotic drug actions on NMDA antagonist responsiveness. Neurosci Biobehav Rev 26:441-455
96. Javitt DC (2004) Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 9:984-997, 979
97. Rosse RB, Theut SK, Banay-Schwartz M, Leighton M, Scarcella E, Cohen CG, Deutsch SI (1989) Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. Clin Neuropharmacol 12:416-424
98. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D (1996) Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 169:610-617
99. Giardino L, Bortolotti F, Orazzo C, Pozza M, Monteleone P, Calza L, Maj M (1997) Effect of chronic clozapine administration on [3H]MK801-binding sites in the rat brain: a side-preference action in cortical areas. Brain Res 762:216-218
100. McCoy L, Cox C, Richfield EK (1998) Antipsychotic drug regulation of AMPA receptor affinity states and GluR1, GluR2 splice variant expression. Synapse 28:195-207
101. Meshul CK, Bunker GL, Mason JN, Allen C, Janowsky A (1996) Effects of subchronic clozapine and haloperidol on striatal glutamatergic synapses. J Neurochem 67:1965-1973
102. Spurney CF, Baca SM, Murray AM, Jaskiw GE, Kleinman JE, Hyde TM (1999) Differential effects of haloperidol and clozapine on ionotropic glutamate receptors in rats. Synapse 34:266-276
103. Tarazi FI, Shirakawa O, Tamminga CA (1993) Low dose raclopride spares the extrapyramidal system in rat brain from metabolic effects. Eur J Pharmacol 232:71-77
104. Healy DJ, Meador-Woodruff JH (1997) Clozapine and haloperidol differentially affect AMPAand kainate receptor subunitmRNA levels in rat cortex and striatum. Brain Res Mol Brain Res 47:331-338
105. Riva MA, Tascedda F, Lovati E, Racagni G (1997) Regulation of NMDA receptor subunit messenger RNA levels in the rat brain following acute and chronic exposure to antipsychotic drugs. Brain Res Mol Brain Res 50:136-142
106. Tascedda F, Blom JM, Brunello N, Zolin K, Gennarelli M, Colzi A, Bravi D, Carra S, Racagni G, Riva MA (2001) Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats. Biol Psychiatry 50:117-122
107. Tarazi FI, Baldessarini RJ, Kula NS, Zhang K (2003) Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment. J Pharmacol Exp Ther 306:1145-1151
108. Jardemark KE, Liang X, Arvanov V, Wang RY (2000) Subchronic treatment with either clozapine, olanzapine or haloperidol produces a hyposensitive response of the rat cortical cells to N-methyl-D-aspartate. Neuroscience 100:1-9
109. Evans RH, Francis AA, Watkins JC (1977) Differential antagonism by chlorpromazine and diazepam of frog motoneurone depolarization induced by glutamate-related amino acids. Eur J Pharmacol 44:325-330
110. Jardemark KE, Ai J, Ninan I, Wang RY (2001) Biphasic modulation of NMDA-induced responses in pyramidal cells of the medial prefrontal cortex by Y-931, a potential atypical antipsychotic drug. Synapse 41:294-300
111. Arvanov VL, Liang X, Schwartz J, Grossman S, Wang RY (1997) Clozapine and haloperidol modulate N-methyl-D-aspartate-and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther 283:226-234
112. Wang RY, Liang X, Jardemark KE, Arvanov V (2000) Facilitation of NMDA transmission by olanzapine. In: Tran PV et al (ed) Olanzapine (Zyprexa) - a novel antipsychotic. Williams &Wilkins, Baltimore, pp 114-131
113. Wittmann M, Marino MJ, Henze DA, Seabrook GR, Conn PJ (2005) Clozapine potentiation of N-methyl-D-aspartate receptor currents in the nucleus accumbens: role of NR2B and protein kinase A/Src kinases. J Pharmacol Exp Ther 313:594-603
114. Arvanov VL, Wang RY (1997) NMDA-induced response in pyramidal neurons of the rat medial prefrontal cortex slices consists of NMDA and non-NMDA components. Brain Res 768:361-364
115. Arvanov VL, Wang RY (1998) M100907, a selective 5-HT2A receptor antagonist and a potential antipsychotic drug, facilitates N-methyl- D-aspartate-receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro. Neuropsychopharmacology 18:197-209
116. Wang X, Gu Z, Zhong P, Chen G, Feng J, Yan Z (2006) Aberrant regulation of NMDA receptors by dopamine D4 signaling in rats after phencyclidine exposure. Mol Cell Neurosci 31:15-25
117. Wang X, Zhong P, Gu Z, Yan Z (2003) Regulation of NMDA receptors by dopamine D4 signaling in prefrontal cortex. J Neurosci 23:9852-9861
118. Ninan I, Jardemark KE, Liang X, Wang RY (2003) Calcium/calmodulin- dependent kinase II is involved in the facilitating effect of clozapine on NMDA- and electrically evoked responses in the medial prefrontal cortical pyramidal cells. Synapse 47:285-294
119. Ilyin VI, Whittemore ER, Guastella J, Weber E, Woodward RM (1996) Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol. Mol Pharmacol 50:1541-1550
120. Levine JB, Martin G, Wilson A, Treistman SN (2003) Clozapine inhibits isolated N-methyl-D-aspartate receptors expressed in Xenopus oocytes in a subunit specific manner. Neurosci Lett 346:125-128
121. Wassef A, Baker J, Kochan LD (2003) GABA and schizophrenia: a review of basic science and clinical studies. J Clin Psychopharmacol 23:601-640
122. Benes FM, Vincent SL, Marie A, Khan Y (1996) Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. Neuroscience 75:1021-1031
123. Impagnatiello F, Guidotti AR, Pesold C, Dwivedi Y, Caruncho H, Pisu MG, Uzunov DP, Smalheiser NR, Davis JM, Pandey GN, Pappas GD, Tueting P, Sharma RP, Costa E (1998) A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc Natl Acad Sci U S A 95:15718-15723
124. Benes FM, Vincent SL, Alsterberg G, Bird ED, SanGiovanni JP (1992) Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics. J Neurosci 12:924-929
125. Cotter D, Landau S, Beasley C, Stevenson R, Chana G, MacMillan L, Everall I (2002) The density and spatial distribution of GABAergic neurons, labelled using calcium binding proteins, in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia. Biol Psychiatry 51:377-386
126. Woo TU, Walsh JP, Benes FM (2004) Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D- aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch Gen Psychiatry 61:649-657
127. Benes FM, Wickramasinghe R, Vincent SL, Khan Y, Todtenkopf M (1997) Uncoupling of GABA(A) and benzodiazepine receptor binding activity in the hippocampal formation of schizophrenic brain. Brain Res 755:121-129
128. Dean B, Hussain T, Hayes W, Scarr E, Kitsoulis S, Hill C, Opeskin K, Copolov DL (1999) Changes in serotonin2A and GABA(A) receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex. J Neurochem 72:1593-1599
129. Squires RF, Saederup E (1991) A review of evidence for GABAergic predominance/glutamatergic deficit as a common etiological factor in both schizophrenia and affective psychoses: more support for a continuum hypothesis of "functional" psychosis. Neurochem Res 16:1099-1111
130. Zink M, Schmitt A, May B, Muller B, Demirakca T, Braus DF, Henn FA (2004) Differential effects of long-term treatment with clozapine or haloperidol on GABAA receptor binding and GAD67 expression. Schizophr Res 66:151-157
131. Zorumski CF, Yang J (1988) Non-competitive inhibition of GABA currents by phenothiazines in cultured chick spinal cord and rat hippocampal neurons. Neurosci Lett 92:86-91
132. Agopyan N, Krnjevic K (1993) Effects of trifluoperazine on synaptically evoked potentials and membrane properties of CA1 pyramidal neurons of rat hippocampus in situ and in vitro. Synapse 13:10-19
133. Mozrzymas JW, Barberis A, Michalak K, Cherubini E (1999) Chlorpromazine inhibits miniature GABAergic currents by reducing the binding and by increasing the unbinding rate of GABAA receptors. J Neurosci 19:2474-2488
134. May PR, Van Putten T (1978) Plasma levels of chlorpromazine in schizophrenia; a critical review of the literature. Arch Gen Psychiatry 35:1081-1087
135. Ikemoto S, Kohl RR, McBride WJ (1997) GABA(A) receptor blockade in the anterior ventral tegmental area increases extracellular levels of dopamine in the nucleus accumbens of rats. J Neurochem 69:137-143
136. Johnson SW, North RA (1992) Two types of neurone in the rat ventral tegmental area and their synaptic inputs. J Physiol 450:455-468
137. Steffensen SC, Svingos AL, Pickel VM, Henriksen SJ (1998) Electrophysiological characterization of GABAergic neurons in the ventral tegmental area. J Neurosci 18:8003-8015
138. Wong G, Kuoppamaki M, Hietala J, Luddens H, Syvalahti E, Korpi ER (1996) Effects of clozapine metabolites and chronic clozapine treatment on rat brain GABAA receptors. Eur J Pharmacol 314:319-323
139. Squires RF, Saederup E (1997) Clozapine and some other antipsychotic drugs may preferentially block the same subset of GABA(A) receptors. Neurochem Res 22:151-162
140. Squires RF, Saederup E (1998) Clozapine and several other antipsychotic/antidepressant drugs preferentially block the same 'core' fraction of GABA(A) receptors. Neurochem Res 23:1283-1290
141. Korpi ER, Wong G, Luddens H (1995) Subtype specificity of gamma-aminobutyric acid type A receptor antagonism by clozapine. Naunyn Schmiedebergs Arch Pharmacol 352:365-373
142. Michael FJ, Trudeau LE (2000) Clozapine inhibits synaptic transmission at GABAergic synapses established by ventral tegmental area neurones in culture. Neuropharmacology 39, 1536-1543
143. Silverstone PH, Greenshaw AJ (1996) 5-HT3 receptor antagonists. Expert Opin Ther Pat 6:471-481
144. Reynolds GP (1992) Developments in the drug treatment of schizophrenia. Trends Pharmacol Sci 13:116-121 [erratum in Trends Pharmacol Sci 1992 Apr;13(4):140; Trends Pharmacol Sci 1992 May;13(5):184]
145. De Deurwaerdere P, Stinus L, Spampinato U (1998) Opposite change of in vivo dopamine release in the rat nucleus accumbens and striatum that follows electrical stimulation of dorsal raphe nucleus: role of 5-HT3 receptors. J Neurosci 18:6528-6538
146. Blandina P, Goldfarb J, Green JP (1988) Activation of a 5-HT3 receptor releases dopamine from rat striatal slice. Eur J Pharmacol 155:349-350
147. Sorensen SM, Humphreys TM, Palfreyman MG (1989) Effect of acute and chronic MDL 73,147EF, a 5-HT3 receptor antagonist, on A9 and A10 dopamine neurons. Eur J Pharmacol 163:115-118
148. Costall B, Domeney AM, Naylor RJ, Tyers MB (1987) Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmacol 92:881-894
149. Wang RY, Ashby CRJ, Zhang JY (1996) Modulation of the A10 dopamine system: electrophysiological studies of the role of 5-HT3-like receptors. Behav Brain Res 73:7-10
150. Apud JA (1993) The 5-HT3 receptor in mammalian brain: a new target for the development of psychotropic drugs? (review, 112 refs). Neuropsychopharmacology 8:117-130
151. Watling KJ, Beer MS, Stanton JA, Newberry NR (1990) Interaction of the atypical neuroleptic clozapine with 5-HT3 receptors in the cerebral cortex and superior cervical ganglion of the rat. Eur J Pharmacol 182:465-472
152. Hermann B, Wetzel CH, Pestel E, Zieglgansberger W, Holsboer F, Rupprecht R (1996) Functional antagonistic properties of clozapine at the 5-HT3 receptor. Biochem Biophys Res Commun 225:957-960
153. Rammes G, Eisensamer B, Ferrari U, ShapaM, Gimpl G, Gilling K, Parsons C, Riering K, Hapfelmeier G, Bondy B, Zieglgansberger W, Holsboer F, Rupprecht R (2004) Antipsychotic drugs antagonize human serotonin type 3 receptor currents in a noncompetitive manner. Mol Psychiatry 9:846-858
154. Greenshaw AJ (1993) Behavioural pharmacology of 5-HT3 receptor antagonists: a critical update on therapeutic potential. Trends Pharmacol Sci 14:265-270
155. Adler LE, Olincy A, Waldo M, Harris JG, Griffith J, Stevens K, Flach K, Nagamoto H, Bickford P, Leonard S, Freedman R (1998) Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull 24:189-202
156. Leonard S, Adler LE, Benhammou K, Berger R, Breese CR, Drebing C, Gault J, Lee MJ, Logel J, Olincy A, Ross RG, Stevens K, Sullivan B, Vianzon R, Virnich DE, Waldo M, Walton K, Freedman R (2001) Smoking and mental illness. Pharmacol Biochem Behav 70:561-570
157. Thaker GK (2002) Current progress in schizophrenia research: sensory gating deficit in schizophrenia: is the nicotinic alpha-7 receptor implicated? J Nerv Ment Dis 190:550-551
158. Sershen H, Balla A, Lajtha A, Vizi ES (1997) Characterization of nicotinic receptors involved in the release of noradrenaline from the hippocampus. Neuroscience 77:121-130
159. Wonnacott S (1997) Presynaptic nicotinic ACh receptors. Trends Neurosci 20:92-98
160. Benoit P, Changeux JP (1993) Voltage dependencies of the effects of chlorpromazine on the nicotinic receptor channel from mouse muscle cell line So18. Neurosci Lett 160:81-84